Teriparatide
Performance & EnduranceRecombinant PTH fragment for osteoporosis, FDA-approved bone-building medication.
Key Benefits
- ✓Increases bone mineral density
- ✓Reduces fracture risk
- ✓Stimulates bone formation
- ✓Treats severe osteoporosis
- ✓Improves bone microarchitecture
Dosing Information
Detailed Protocol
Administered via subcutaneous injection once daily, typically in the thigh. Treatment limited to 2 years lifetime. Requires prescription and medical supervision.
About Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), the bioactive N-terminal fragment of PTH. It stimulates osteoblast activity and builds new bone. FDA-approved for severe osteoporosis in both men and women.
Research Notes
FDA-approved in 2002. Extensive clinical use showing significant fracture risk reduction. First anabolic agent for osteoporosis. Lifetime treatment limit due to rat osteosarcoma findings.
Potential Side Effects
- •Hypercalcemia
- •Nausea
- •Dizziness
- •Leg cramps
- •Black box warning for osteosarcoma in rats
Always consult with a healthcare professional before starting any peptide therapy.